BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Goldacre B, van Staa T, MacDonald TM, Armitage J, Wimborne J, Melrose P, Singh J, Brooks L, Moore M, Hoffman M, Smeeth L; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 2021;372:n135. [PMID: 33627334 DOI: 10.1136/bmj.n135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Orringer CE, Grant JK, Tokgozoglu L. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms. Curr Atheroscler Rep 2022. [PMID: 36001213 DOI: 10.1007/s11883-022-01059-x] [Reference Citation Analysis]
2 Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik M. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2022;328:754-71. [PMID: 35997724 DOI: 10.1001/jama.2022.12138] [Reference Citation Analysis]
3 Khouri C, Larabi A, Verger P, Gauna F, Cracowski JL, Ward J. Impact of Vaccine Hesitancy on Onset, Severity and Type of Self-reported Adverse Events: A French Cross-Sectional Survey. Drug Saf 2022. [PMID: 35972651 DOI: 10.1007/s40264-022-01220-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Blazing M, Braunwald E, de Lemos J, Murphy S, Pedersen T, Pfeffer M, White H, Wiviott S, Clearfield M, Downs JR, Gotto, Jr A, Weis S, Fellström B, Holdaas H, Jardine A, Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield J, Rahman M, Simpson L, Koren M, Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H, Knopp (deceased) R, Cobbe S, Schmieder R, Zannad F, Betteridge DJ, Colhoun H, Durrington P, Fuller (deceased) J, Hitman GA, Neil A, Hawkins CM, Moyé L, Sacks F, Kjekshus J, Wikstrand J, Wanner C, Krane V, Franzosi MG, Latini R, Lucci D, Maggioni A, Marchioli R, Nicolis E, Tavazzi L, Tognoni G, Bosch J, Lonn E, Yusuf S, Armitage J, Bowman L, Collins R, Keech A, Landray M, Parish S, Peto R, Sleight P, Kastelein J, Glynn R, Koenig W, Macfadyen J, Ridker P, Macmahon S, Marschner I, Tonkin A, Shaw J, Simes J, Serruys P, Knatterud (deceased) G, Ford I, Macfarlane P, Packard C, Sattar N, Shepherd J, Trompet S, Cannon CP, Amarenco P, Welch KM, Wilhelmsen L, Barter P, Larosa J, Kean S, Robertson M, Young R, Arashi H, Clarke R, Flather M, Goto S, Goldbourt U, Hopewell J, Hovingh K, Kitas G, Newman C, Sabatine MS, Schwartz G, Smeeth L, Tobert J, Varigos J, Yamaguchi J, Kearney P, Jukema JW, Byington R. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)01545-8] [Reference Citation Analysis]
5 Tobert JA. LDL Cholesterol—How Low Can We Go? Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.01.005] [Reference Citation Analysis]
6 Newman CB. Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2022.01.004] [Reference Citation Analysis]
7 Abushamat LA, Ballantyne CM. Lowering LDL cholesterol in clinical practice: time for change? The Lancet 2022;400:341-3. [DOI: 10.1016/s0140-6736(22)01352-6] [Reference Citation Analysis]
8 Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol 2022:S1933-2874(22)00167-2. [PMID: 35718660 DOI: 10.1016/j.jacl.2022.05.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tudor K, Brooks J, Howick J, Fox R, Aveyard P. Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care. Circ Cardiovasc Qual Outcomes 2022;15:e007793. [PMID: 35698974 DOI: 10.1161/CIRCOUTCOMES.120.007793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Howard J, Rajasundaram S. Role of Blinding in N-of-1 Trials. Circ Cardiovasc Qual Outcomes 2022;15:e008914. [PMID: 35698975 DOI: 10.1161/CIRCOUTCOMES.122.008914] [Reference Citation Analysis]
11 Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, Calvert SB, Gallagher K, Pagidipati NJ, Granger CB. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. J Am Coll Cardiol 2022;79:1802-13. [PMID: 35512860 DOI: 10.1016/j.jacc.2022.02.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hao Q, Aertgeerts B, Guyatt G, Bekkering GE, Vandvik PO, Khan SU, Rodondi N, Jackson R, Reny JL, Al Ansary L, Van Driel M, Assendelft WJJ, Agoritsas T, Spencer F, Siemieniuk RAC, Lytvyn L, Heen AF, Zhao Q, Riaz IB, Ramaekers D, Okwen PM, Zhu Y, Dawson A, Ovidiu MC, Vanbrabant W, Li S, Delvaux N. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ 2022;377:e069066. [PMID: 35508320 DOI: 10.1136/bmj-2021-069066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
13 Stürzebecher PE, Schumann F, Kassner U, Laufs U. [Statin intolerance and statin-associated muscular pain]. Herz 2022. [PMID: 35451596 DOI: 10.1007/s00059-022-05114-w] [Reference Citation Analysis]
14 Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ 2022;376:e067731. [PMID: 35331984 DOI: 10.1136/bmj-2021-067731] [Reference Citation Analysis]
15 Penson PE, Bruckert E, Marais D, Reiner Ž, Pirro M, Sahebkar A, Bajraktari G, Mirrakhimov E, Rizzo M, Mikhailidis DP, Sachinidis A, Gaita D, Latkovskis G, Mazidi M, Toth PP, Pella D, Alnouri F, Postadzhiyan A, Yeh H, Mancini GJ, von Haehling S, Banach M, Acosta J, Al‐khnifsawi M, Alnouri F, Amar F, Atanasov AG, Bajraktari G, Banach M, Bhaskar S, Bytyçi I, Bjelakovic B, Bruckert E, Cafferata A, Ceska R, Cicero AF, Collet X, Daccord M, Descamps O, Djuric D, Durst R, Ezhov MV, Fras Z, Gaita D, Hernandez AV, Jones SR, Jozwiak J, Kakauridze N, Kallel A, Katsiki N, Khera A, Kostner K, Kubilius R, Latkovskis G, Mancini GJ, Marais AD, Martin SS, Martinez JA, Mazidi M, Mikhailidis DP, Mirrakhimov E, Miserez AR, Mitchenko O, Mitkovskaya NP, Moriarty PM, Nabavi SM, Nair D, Panagiotakos DB, Paragh G, Pella D, Penson PE, Petrulioniene Z, Pirro M, Postadzhiyan A, Puri R, Reda A, Reiner Ž, Radenkovic D, Rakowski M, Riadh J, Richter D, Rizzo M, Ruscica M, Sahebkar A, Sattar N, Serban M, Shehab AM, Shek AB, Sirtori CR, Stefanutti C, Tomasik T, Toth PP, Viigimaa M, Valdivielso P, Vinereanu D, Vohnout B, von Haehling S, Vrablik M, Wong ND, Yeh H, Zhisheng J, Zirlik A; International Lipid Expert Panel (ILEP). Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J cachexia sarcopenia muscle 2022;13:1596-622. [DOI: 10.1002/jcsm.12960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Sverre E, Peersen K, Kristiansen O, Fagerland MW, Perk J, Husebye E, Vethe NT, Dammen T, Munkhaugen J. Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self-perceived muscle side effects. J Intern Med 2022. [PMID: 35103360 DOI: 10.1111/joim.13454] [Reference Citation Analysis]
17 Garshick MS, Berger JS. Psoriasis and Cardiovascular Disease-An Ounce of Prevention Is Worth a Pound of Cure. JAMA Dermatol 2022. [PMID: 35044422 DOI: 10.1001/jamadermatol.2021.4723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Tokgozoglu L, Orringer C, Ginsberg HN, Catapano AL. The year in cardiovascular medicine 2021: dyslipidaemia. Eur Heart J 2022:ehab875. [PMID: 34974612 DOI: 10.1093/eurheartj/ehab875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Gaffney AW. The Long COVID Conundrum. Am J Med 2022;135:5-6. [PMID: 34428463 DOI: 10.1016/j.amjmed.2021.07.037] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, Perk J, Husebye E, Dammen T. Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovasc Disord 2021;21:596. [PMID: 34915854 DOI: 10.1186/s12872-021-02422-7] [Reference Citation Analysis]
21 Metser G, Bradley C, Moise N, Liyanage-Don N, Kronish I, Ye S. Gaps and Disparities in Primary Prevention Statin Prescription During Outpatient Care. Am J Cardiol 2021;161:36-41. [PMID: 34794616 DOI: 10.1016/j.amjcard.2021.08.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Nishikido T, Ray KK. The power of lipid registries for cardiovascular disease prevention. Curr Opin Lipidol 2021;32:342-8. [PMID: 34561312 DOI: 10.1097/MOL.0000000000000783] [Reference Citation Analysis]
23 Senn S, Chalmers I. Giving and taking: ethical treatment assignment in controlled trials. J R Soc Med 2021;114:525-30. [PMID: 34802321 DOI: 10.1177/01410768211049972] [Reference Citation Analysis]
24 Kohli-Lynch CN, Bellows BK, Zhang Y, Spring B, Kazi DS, Pletcher MJ, Vittinghoff E, Allen NB, Moran AE. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. J Am Coll Cardiol 2021;78:1954-64. [PMID: 34763772 DOI: 10.1016/j.jacc.2021.08.065] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Orringer CE, Blaha MJ, Stone NJ. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. J Clin Lipidol 2021;15:782-8. [PMID: 34688585 DOI: 10.1016/j.jacl.2021.09.052] [Reference Citation Analysis]
26 Melhem AL, Chourasia MK, Bigossi M, Maroteau C, Taylor A, Pola R, Dawed AY, Tornio A, Palmer CNA, Siddiqui MK. Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Front Genet 2021;12:713181. [PMID: 34659336 DOI: 10.3389/fgene.2021.713181] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Elvir-Lazo OL, White PF, Cruz Eng H, Yumul F, Chua R, Yumul R. Impact of chronic medications in the perioperative period -anesthetic implications (Part II). Postgrad Med 2021;:1-19. [PMID: 34551658 DOI: 10.1080/00325481.2021.1982298] [Reference Citation Analysis]
28 Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, Rajkumar CA, Connolly S, Cegla J, Stride C, Sever P, Norton C, Thom SAM, Shun-Shin MJ, Francis DP. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol 2021;78:1210-22. [PMID: 34531021 DOI: 10.1016/j.jacc.2021.07.022] [Reference Citation Analysis]
29 Nikles J, Onghena P, Vlaeyen JWS, Wicksell RK, Simons LE, McGree JM, McDonald S. Establishment of an International Collaborative Network for N-of-1 Trials and Single-Case Designs. Contemp Clin Trials Commun 2021;23:100826. [PMID: 34401597 DOI: 10.1016/j.conctc.2021.100826] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Villoz F, Lyko C, Del Giovane C, Rodondi N, Blum MR. Tolerability of statin-based management of patients with a history of statin-associated muscle symptoms: protocol for a systematic review. BMJ Open 2021;11:e052341. [PMID: 34344686 DOI: 10.1136/bmjopen-2021-052341] [Reference Citation Analysis]
31 Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, Lay-Flurrie S, Koshiaris C, McManus RJ, Hobbs FDR, Sheppard JP. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021;374:n1537. [PMID: 34261627 DOI: 10.1136/bmj.n1537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
32 Diaconu CC, Iorga RA, Furtunescu F, Katsiki N, Stoian AP, Rizzo M. Statin intolerance: new data and further options for treatment. Curr Opin Cardiol 2021;36:487-93. [PMID: 33929368 DOI: 10.1097/HCO.0000000000000874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Penson PE, Banach M. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. Eur Heart J 2021:ehab358. [PMID: 34151941 DOI: 10.1093/eurheartj/ehab358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
34 Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open 2021;11:e043714. [PMID: 34130955 DOI: 10.1136/bmjopen-2020-043714] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Liuzzo G, Patrono C. StatinWISE sheds new light on statin-related muscle symptoms. Eur Heart J 2021;42:1726-7. [PMID: 33961023 DOI: 10.1093/eurheartj/ehab220] [Reference Citation Analysis]
36 Hirsh Raccah B, Yanovsky A, Treves N, Rotshild V, Renoux C, Danenberg H, Eliaz R, Matok I. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. Int J Cardiol 2021;335:7-14. [PMID: 33892045 DOI: 10.1016/j.ijcard.2021.04.025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Husain M. Time for N-of-1 trials in clinical decision-making. Brain 2021;144:1031-2. [PMID: 33871604 DOI: 10.1093/brain/awab107] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Herrett E, Williamson E, Brack K, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Beaumont D, Jamal Z, Goldacre B, van Staa T, MacDonald TM, Armitage J, Moore M, Hoffman M, Smeeth L. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess 2021;25:1-62. [PMID: 33709907 DOI: 10.3310/hta25160] [Reference Citation Analysis]
39 Mahase E. Statins have no overall effect on frequency or severity of muscle symptoms, study finds. BMJ 2021;372:n553. [PMID: 33627332 DOI: 10.1136/bmj.n553] [Reference Citation Analysis]